A

Alliance Pharma PLC
LSE:APH

Watchlist Manager
Alliance Pharma PLC
LSE:APH
Watchlist
Price: 39.201 GBX 1.56%
Updated: May 24, 2024

P/E
Price to Earnings

-30
Current
30.1
Median
23.5
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-30
=
Market Cap
211.7m
/
Net Income
-7.1m
All Countries
Close
Earnings Growth
UK
A
Alliance Pharma PLC
LSE:APH
Average P/E: 55.7
Negative Multiple: -30
2 955%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
125.2
346%
DK
Novo Nordisk A/S
CSE:NOVO B
46.4
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-21%
US
Merck & Co Inc
NYSE:MRK
144
7 453%
UK
AstraZeneca PLC
LSE:AZN
38.1
168%
CH
Roche Holding AG
SIX:ROG
16.1
26%
CH
Novartis AG
SIX:NOVN
11.2
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -526.2
680%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
hidden
2-Years Forward
P/E
hidden
3-Years Forward
P/E
hidden

See Also

Discover More